What is the 13F Pro Quality Score for CING?

13F Pro ranks Cingulate Inc. (CING) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View CING's current score at https://13fpro.ai/research/CING (free sign-up required for the full ranking).

Where does 13F Pro source CING data?

All Cingulate Inc. fundamentals and ownership data come directly from SEC EDGAR. Cingulate Inc. files with the SEC under CIK 1862150. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is CING in?

Cingulate Inc. (CING) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is CING research updated on 13F Pro?

CING's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Cingulate Inc.(CING)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1862150 CING stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.0M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

CING Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Cingulate Inc. (CING), a Healthcare sector company. CING is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Based on the latest XBRL financial filings (Q1 2026), Cingulate Inc. reports net income of $-9.3M, free cash flow of $-7.0M. Top institutional holders of CING by reported 13-F value include VANGUARD CAPITAL MANAGEMENT, Kestra Advisory Services,, GEODE CAPITAL MANAGEMENT,, based on the most recent SEC filings. CING trades on the Nasdaq exchange and files with the SEC under CIK 1862150. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CING daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Cingulate Inc. directly from SEC EDGAR.

Net Income

Q1 2026

$-9.3M

Free Cash Flow

Q1 2026

$-7.0M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Net Income

-35.6% YoY

$-22.4MFY 2025

FY22 $-17.7MFY23 $-23.5MFY24 $-16.6MFY25 $-22.4M

Operating Income

-27.4% YoY

$-19.9MFY 2025

FY22 $-17.5MFY23 $-22.8MFY24 $-15.6MFY25 $-19.9M

EPS (Diluted)

+59.1% YoY

$-4.44FY 2025

FY22 $-7.34FY23 $-78.00FY24 $-10.86FY25 $-4.44

Total Assets

+1.4% YoY

$15.1MFY 2025

FY22 $11.4MFY23 $3.5MFY24 $14.9MFY25 $15.1M

Op. Cash Flow

+6.5% YoY

$-17.2MFY 2025

FY22 $-15.9MFY23 $-15.0MFY24 $-18.5MFY25 $-17.2M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Net Income	$-22.4M -35.6%	$-16.6M +29.6%	$-23.5M -33.1%	$-17.7M +14.6%	$-20.7M -188.3%	$-7.2M
Operating Income	$-19.9M -27.4%	$-15.6M +31.3%	$-22.8M -30.0%	$-17.5M +15.4%	$-20.7M -191.9%	$-7.1M
EPS (Diluted)	$-4.44 +59.1%	$-10.86 +86.1%	$-78.00 -963.0%	$-7.34	—	—
Total Assets	$15.1M +1.4%	$14.9M +325.7%	$3.5M -69.4%	$11.4M -50.2%	$22.9M +295.4%	$5.8M
Operating Cash Flow	$-17.2M +6.5%	$-18.5M -22.7%	$-15.0M +5.3%	$-15.9M -52.2%	$-10.4M -53.2%	$-6.8M

AI Insight: CING Financial Trends

Cingulate's cash burn and operating losses have accelerated in Q1 2026, with equity volatility masking persistent unprofitability.

• Operating loss widened to $8M in Q1 2026 from $6M in Q4 2025; operating cash outflow increased to $7M.

• Net loss deteriorated to $9M in Q1 2026, the largest quarterly loss in the dataset spanning eight quarters.

• Equity rebounded to $19M in Q1 2026 from $3M in Q4 2025, likely driven by capital raise rather than operational improvement.

⚠ Operating and net losses have trended worse Q4 2025–Q1 2026 despite apparent equity infusion; no revenue visibility.

⚠ Operating cash outflow accelerated; cumulative burn over eight quarters exceeds $35M with no profitability inflection.

AI Insight: CING Ratio Trends

Cingulate remains deeply unprofitable with ROE deteriorating to -197.4% in Q1 2026, reflecting persistent operating losses and negative equity.

• ROE worsened from -137.8% in Q3 2024 to -197.4% in Q1 2026, signaling deepening losses relative to shareholder capital.

• TTM ROE and ROA both severely negative (-147.9% and -90.4% respectively), indicating sustained unprofitability across trailing twelve months.

⚠ Majority of quarterly profitability metrics are blank; insufficient data to assess operational trends or runway.

⚠ ROE deterioration accelerating (Q3 2024: -137.8% → Q1 2026: -197.4%) suggests losses outpacing equity base.

Get alerted when CING's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Cingulate Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of CING

VANGUARD CAPITAL MANAGEMENT LLC
$1.9M308,967 sh
Kestra Advisory Services, LLC
$869.4K140,000 sh
GEODE CAPITAL MANAGEMENT, LLC
$629.8K101,373 sh
MARSHALL WACE, LLP
$577.1K92,934 sh
JANE STREET GROUP, LLC
$564.3K90,867 sh
XTX Topco Ltd
$332.3K53,503 sh
BCV Asset Management Inc.
$317.9K51,200 sh
VANGUARD FIDUCIARY TRUST CO
$311.0K50,074 sh
Quadrature Capital Ltd
$216.3K34,839 sh
RENAISSANCE TECHNOLOGIES LLC
$198.0K31,888 sh

Fund	Value	Shares
VANGUARD CAPITAL MANAGEMENT LLC	$1.9M	308,967
Kestra Advisory Services, LLC	$869.4K	140,000
GEODE CAPITAL MANAGEMENT, LLC	$629.8K	101,373
MARSHALL WACE, LLP	$577.1K	92,934
JANE STREET GROUP, LLC	$564.3K	90,867
XTX Topco Ltd	$332.3K	53,503
BCV Asset Management Inc.	$317.9K	51,200
VANGUARD FIDUCIARY TRUST CO	$311.0K	50,074
Quadrature Capital Ltd	$216.3K	34,839
RENAISSANCE TECHNOLOGIES LLC	$198.0K	31,888

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put CING on your watchlist

Track score changes the day Cingulate Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is CING a good stock to buy?

13F Pro's AI-powered analysis of Cingulate Inc. (CING) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CING are available on the CING stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own CING?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CING. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Cingulate Inc.'s investment landscape.